Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma

NCT05243342 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT05243342
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05243342 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 28, 2022
Completion date
July 10, 2024
Enrollment
18 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma